Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRevenue - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Cartesian Therapeutics (RNAC) Other Gross PP&E Adjustments (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Other Gross PP&E Adjustments for 12 consecutive years, with $11.6 million as the latest value for Q1 2026.

  • For Q1 2026, Other Gross PP&E Adjustments rose 49.9% year-over-year to $11.6 million; the TTM value through Mar 2026 reached $11.6 million, up 49.9%, while the annual FY2025 figure was $8.7 million, 53.88% up from the prior year.
  • Other Gross PP&E Adjustments hit $11.6 million in Q1 2026 for Cartesian Therapeutics, up from $8.7 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $11.6 million in Q1 2026 and bottomed at -$4.1 million in Q3 2022.
  • Average Other Gross PP&E Adjustments over 5 years is $2.2 million, with a median of -$1.2 million recorded in 2024.
  • Year-over-year, Other Gross PP&E Adjustments tumbled 104.48% in 2023 and then soared 1024.5% in 2025.
  • Cartesian Therapeutics' Other Gross PP&E Adjustments stood at -$1.1 million in 2022, then crashed by 104.48% to -$2.2 million in 2023, then surged by 353.42% to $5.7 million in 2024, then soared by 53.88% to $8.7 million in 2025, then skyrocketed by 33.31% to $11.6 million in 2026.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at $11.6 million, $8.7 million, and $11.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.